Islatravir Once Monthly for PrEP Demonstrates Favorable Safety/Tolerability and Meets Pharmacokinetic Threshold Target in Blinded Interim Analysis of Phase IIa Trial

January 27-28 and February 3-4, 2021
Interim analysis showed that islatravir administered once monthly achieved the prespecified pharmacokinetic threshold for predicted HIV pre-exposure prophylaxis efficacy.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: January 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) presents expert faculty discussing the barriers and solutions to expanding PrEP uptake, from a nursing perspective

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Christopher Fox, MSN, RN, ANP-BC, AAHIVS
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2022 Expired: June 13, 2023

Dr Michelle Collins-Ogle and Clinical Care Options (CCO): HIV postexposure prophylaxis is recommended following a potential sexual exposure.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 26, 2022

Clinical Care Options (CCO): expert commentary on major findings from EPIC-NSW and next steps in PrEP strategies and populationwide HIV prevention efforts

Prof. Don Smith Released: March 18, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): There are key management considerations for patients initiating LA cabotegravir for PrEP

person default Jason Schafer, PharmD, MPH Released: March 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings